跳至主要内容
临床试验/NCT00837629
NCT00837629已完成不适用

An Open-label Non-interventional Evaluation of Efficacy of Symbicort® Forte Turbuhaler 320/9 µg (Budesonide / Formoterol) and Symbicort® Turbuhaler® 160/4,5 µg (Budesonide / Formoterol)in Functional Status Improvement of Patients With Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca0 个研究点目标入组 743 人开始时间: 2007年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
743
主要终点
Reduction in overall Clinical COPD Questionnaire (CCQ) score

研究概览

简要总结

This non-interventional study is to analyse the therapeutic effectiveness in patients with severe COPD following a generally accepted 12-week treatment period with Symbicort Turbuhaler, which could anyhow be shortened or extended at physician's discretion.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • non pregnant female
  • COPD with persistent symptoms in spite of regular bronchodilator therapy
  • Naive or fixed combination treated patients including patients already on Symbicort Turbuhaler

排除标准

  • Hypersensitivity to budesonide, formoterol or inhaled lactose

结局指标

主要结局

Reduction in overall Clinical COPD Questionnaire (CCQ) score

时间窗: 12 weeks

次要结局

  • Patient satisfaction(12 weeks)
  • Physicians' global clinical impression of the treatment(12 weeks)
  • Evaluation of smoking habits(12 weeks)

研究者

发起方
AstraZeneca
申办方类型
Industry

相似试验